Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093826 | 0.76 | ALDH1A1 (0.43) | MAPTALDH1A1TP53GAATSHR | |
| SCHEMBL2090253 | 0.74 | C1R (0.37) | MAPTALDH1A1TP53GAATSHR | |
| SCHEMBL12651732 | 0.74 | LMNA (0.50) | MAPTALDH1A1TP53GAATSHR | |
| SCHEMBL25939297 | 0.74 | TRIM24 (0.41) | MAPTALDH1A1TP53GAATSHR | |
| SCHEMBL9462171 | 0.74 | MAPT (0.33) | MAPTALDH1A1TP53GAATSHR | |
| SCHEMBL2089948 | 0.74 | ALDH1A1 (0.38) | MAPTALDH1A1TP53GAATSHR | |
| SCHEMBL2697491 | 0.74 | CHEK1 (0.41) | MAPTALDH1A1TP53GAATSHR | |
| SCHEMBL2092841 | 0.74 | ACHE (0.36) | MAPTALDH1A1TP53GAATSHR | |
| SCHEMBL1037466 | 0.74 | CHEK1 (0.48) | MAPTALDH1A1TP53GAATSHR | |
| SCHEMBL7717253 | 0.72 | ALDH1A1 (0.32) | MAPTALDH1A1TP53GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772502-B2 | Alkylsulfinyl-substituted thiazolide compounds | ROMARK LABORATORIES, L.C. (US) | 2014-07-08 | — | — | US | claimed |
| EP-2635124-A1 | ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | Romark Laboratories, L.C. (US) | 2013-09-11 | — | — | EP | claimed |
| WO-2012061190-A1 | ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES L.C. (US) | 2012-05-10 | — | — | WO | claimed |
| WO-2012058378-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES L.C. (US) | 2012-05-03 | — | — | WO | claimed |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | claimed |
| US-20120108591-A1 | ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | claimed |
| US-8772502-B2 | Alkylsulfinyl-substituted thiazolide compounds | ROMARK LABORATORIES, L.C. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2635124-A1 | ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | Romark Laboratories, L.C. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061190-A1 | ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES L.C. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012058378-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES L.C. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108591-A1 | ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | PYGL, GYS2, GLS2 | MAPT 3233/4885ALDH1A1 533/4885TP53 281/4885 |
| US-20120108591-A1 | ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | HAVCR2, EIF2AK2, HCCS | MAPT 4209/4885ALDH1A1 1483/4885TP53 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.